


**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61L 9/04, A61K 9/12</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/25184</b> <b>(43) International Publication Date:</b> 22 August 1996 (22.08.96)
<b>(21) International Application Number:</b> PCT/US96/01745 <b>(22) International Filing Date:</b> 8 February 1996 (08.02.96) <b>(30) Priority Data:</b> 08/389,304 16 February 1995 (16.02.95) US <b>(71) Applicant:</b> THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02114 (US). <b>(72) Inventors:</b> ZAPOL, Warren, M.; 182 Holden Wood Road, Concord, MA 01742 (US). BLOCH, Kenneth, D.; Apartment 313, 20 Webster Street, Brookline, MA 02146 (US). <b>(74) Agent:</b> FRASER, Janis, K.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	

**(54) Title:** TREATMENT OF VASCULAR THROMBOSIS AND RESTENOSIS WITH INHALED NITRIC OXIDE**(57) Abstract**

Disclosed are methods of treating, inhibiting or preventing vascular thrombosis or arterial restenosis in a mammal. The disclosed methods include causing the mammal to inhale a therapeutically-effective concentration of gaseous nitric oxide (NO). Also disclosed are methods that include the administration of the following types of agents in conjunction with inhaled nitric oxide: compounds that potentiate the beneficial effects of inhaled nitric oxide, and antithrombotic agents that complement or supplement the beneficial effects of inhaled nitric oxide. The figure is a graph comparing the intima/media ratio in control rats, rats exposed for two weeks to 20 ppm NO, and rats exposed for one week to 80 ppm NO, followed by one week of breathing air. The asterisk indicates values significantly differing from baseline ( $p < 0.05$ ).

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TREATMENT OF VASCULAR THROMBOSIS AND  
RESTENOSIS WITH INHALED NITRIC OXIDE

Statement as to Federally Sponsored Research

5 Work on this invention was supported, in part, with funds from the United States government (USPHS grants HL42397 and HL45895). The government therefore has certain rights in the invention.

Background of the Invention

10 This invention relates to methods of treating, inhibiting or preventing vascular thrombosis and methods of treating, inhibiting or preventing arterial restenosis resulting from excessive intimal hyperplasia.

A thrombosis, i.e., the formation or presence of a  
15 blood clot within a blood vessel, may result from physical injury of an arterial wall by a vascular interventional procedure such as percutaneous transluminal coronary angioplasty ("PTCA"; a type of balloon angioplasty) or coronary bypass surgery.  
20 Thrombosis may also result from progression of a natural disease, such as atherosclerosis. Various agents, including aspirin, prostaglandin E<sub>1</sub>, selective thromboxane A<sub>2</sub> inhibitors, selective thrombin inhibitors, platelet receptor GPIIb/IIIa blockers, tissue plasminogen  
25 activator, streptokinase, heparin and kistrin have been used as antithrombotics. See, e.g., Yasuda et al. (Circulation 83:1038 (1991)); and Gold et al., (Circulation (Supplement IV) 83:IV26 (1991)). Currently available antiplatelet agents include aspirin,  
30 ticlopidin, monoclonal antibodies, nitroglycerin and sodium nitroprusside.

Another unwanted result of arterial injury from vascular interventional procedures is arterial  
restenosis. For example, PTCA has been used extensively  
35 to open occluded arteries in both the coronary and peripheral vascular systems. Although initially

successful in over 95 percent of cases, a gradual renarrowing or reocclusion process, known as restenosis, occurs within six months in 30 to 50 percent of the patients.

5           Vascular interventional procedures tend to damage the vascular wall. Such injury triggers the proliferation of vascular smooth muscle cells, resulting in intimal hyperplasia. This proliferation may be due in part to the effects of platelet-derived growth factors  
10 released by platelets which adhere to the site of arterial injury. Excessive intimal hyperplasia leads to restenosis, i.e., a re-narrowing of the arterial lumen. Thus, arterial restenosis can severely limit the long-term effectiveness of vascular interventional procedures.

15                           Summary of the Invention

          It has been discovered that inhaled nitric oxide (NO) gas increases blood vessel patency after lysis of a thrombus at the site of a critical stenosis, without causing any systemic hemodynamic effects. The  
20 antithrombotic effects of inhaled NO persist after the cessation of NO inhalation. It has also been discovered that inhaled NO inhibits arterial restenosis resulting from excessive intimal hyperplasia.

          Accordingly, in one aspect, the invention features  
25 a method for treating, inhibiting or preventing a thrombosis in a mammal, by causing the mammal to inhale a therapeutically effective amount of gaseous NO. The thrombosis may be associated with a disease or injury.

          In another aspect, the invention features a method  
30 for treating, inhibiting or preventing arterial restenosis in a mammal, by causing the mammal to inhale a therapeutically effective amount of gaseous NO. The arterial restenosis may be associated with a disease or injury.

A second compound which potentiates the beneficial effects of inhaled NO may be administered to a mammal, in conjunction with NO inhalation. One means whereby the second compound could potentiate the beneficial effects of NO inhalation is by prolongation of the effect of inhaled NO in target tissues, or cells that interact with the target tissues, without causing undesirable systemic vasodilation and concomitant decrease in systemic blood pressure. More particularly, prolonging the antithrombotic and/or intimal hyperplasia-inhibiting effect of inhaled NO may be accomplished by administering a phosphodiesterase-inhibiting agent in conjunction with (i.e., before, during or immediately after) NO inhalation. Preferred phosphodiesterase inhibitors are those that selectively inhibit cGMP-specific phosphodiesterases, while minimally affecting the breakdown of adenosine 3',5'-cyclic monophosphate (cAMP) by other phosphodiesterases. A preferred phosphodiesterase inhibitor displaying the aforementioned specificity is Zaprinast<sup>®</sup> (M&B 22948; 2-o-propoxyphenyl-8-azapurine-6-one, Rhone-Poulenc Rorer, Dagenham Essex, UK). Other cGMP-specific phosphodiesterase inhibitors are known and may be substituted for Zaprinast<sup>®</sup>.

Another means whereby the second compound could potentiate the beneficial effects of NO inhalation is by prolongation of the in vivo half-life of NO. That may be accomplished, for example, by administering superoxide dismutase. Superoxide dismutase removes superoxide radicals, which react with NO.

In other preferred embodiments, a second antithrombotic agent which augments the beneficial antithrombotic effects of inhaled NO may be administered to a mammal in conjunction with the inhaled NO. Examples include aspirin, ticlopidine, monoclonal antibodies, nitroglycerin, and sodium nitroprusside.

As used herein, "acute ischemic coronary syndrome" means acute occlusion of a coronary artery, e.g., acute myocardial infarction, unstable angina, crescendo angina, angina pectoris, coronary intermediate syndrome, angina pectoris status post thrombolysis and angina pectoris status post PTCA.

As used herein, "antithrombotic agent" means an agent that inhibits thrombus formation, stimulates thrombolysis, i.e., thrombus dissolution, or both.

10 As used herein, "intimal (or neointimal) hyperplasia" means proliferation of arterial smooth muscle cells in the intima, in response to arterial endothelial denudation.

As used herein, "revascularization" means  
15 reestablishment of blood supply to a part of the mammalian body.

As used herein, "target cells" means non-pulmonary cells that interact directly with NO, following NO inhalation, to mediate a beneficial effect in the  
20 inhibition, prevention or treatment of thrombosis or arterial restenosis.

As used herein, a "therapeutically effective concentration of gaseous NO" is a concentration that induces one or more of the following in a given patient:  
25 relief of chest pain, relief of shortness of breath, resolution of ischemic electrocardiographic changes, and improved coronary artery blood flow (which may be shown by angiography).

As used herein, a "therapeutically effective"  
30 amount of a phosphodiesterase inhibitor is an amount that increases the duration (i.e., half-time) or magnitude of the therapeutic effect of gaseous NO.

As used herein, "thrombosis" means the formation or presence of a blood clot within a blood vessel, which

- 5 -

clot may cause infarction or ischemia of tissues supplied by the vessel.

As used herein, "arterial restenosis" means an abnormal narrowing of an arterial lumen as a result of excessive (neo)intimal hyperplasia.

As used herein, "vascular interventional procedure" means any surgical procedure that involves an anatomical disruption or a mechanical disturbance of a blood vessel. A non-exclusive list of vascular interventional procedures includes balloon angioplasty, laser angioplasty, coronary artery surgery, atherectomy and coronary artery stents.

The methods herein disclosed are useful for treating, inhibiting or preventing thrombosis, such as may result from a naturally occurring disease, e.g., atherosclerosis, or from a vascular interventional procedure, e.g., angioplasty or coronary bypass surgery. The methods herein disclosed are also useful for treating, inhibiting or preventing arterial restenosis resulting from excessive intimal hyperplasia. Such arterial restenosis is a frequent complication associated with vascular interventional procedures, such as PTCA or coronary bypass surgery.

According to this invention, NO gas may be administered:

- (a) continuously or intermittently;
- (b) in the absence of tobacco smoke;
- (c) at a concentration between 0.1 and 300 parts per million (ppm), preferably between 1.0 and 200 ppm, and most preferably between 20 and 100 ppm;
- (d) as a mixture including NO, oxygen (O<sub>2</sub>), and nitrogen (N<sub>2</sub>) or other inert gases, preferably having an FiO<sub>2</sub> (i.e., proportion of O<sub>2</sub>, by volume) of 0.20 to 0.99, the proportion of O<sub>2</sub> in air being 0.21, and where the NO gas is mixed with the O<sub>2</sub>-containing gas shortly before

inhalation (e.g., less than 5 minutes before inhalation, and preferably less than one minute before inhalation); and

(e) in such a way that the concentration of NO<sub>2</sub> is monitored and kept within safe limits (e.g., less than 1 ppm).

An important advantage of this invention is that inhaled NO does not induce systemic vasodilation and concomitant acute systemic hypotension. Systemic vasodilation is an undesirable, potentially dangerous side effect associated with sustained systemic NO release from oral or intravenously administered NO donor compounds which have been used to inhibit thrombosis or excessive intimal hyperplasia.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

#### Brief Description of the Drawings

Fig. 1A is a graph comparing open arterial time (as a percentage of total time) for the control group before, during and after zero ppm NO inhalation, in the canine coronary artery thrombosis model.

Fig. 1B is a graph comparing open arterial time (as a percentage of total time) for the 20 ppm inhaled NO group before, during and after NO inhalation, in the canine coronary artery thrombosis model. The asterisk indicates value significantly differs from baseline ( $p < 0.05$ ).

Fig. 1C is a graph comparing open arterial time (as a percentage of total time) for the 80 ppm inhaled NO group before, during and after NO inhalation, in the canine coronary artery thrombosis model. The asterisk indicates value significantly differs from baseline ( $p < 0.05$ ).



Fig. 1D is a graph comparing open arterial time (as a percentage of total time) for the 200 ppm inhaled NO group before, during and after NO inhalation, in the canine coronary artery thrombosis model.

5 Fig. 2 is a graph showing ADP-induced canine platelet aggregation curves for samples exposed to 0 ppm NO or 400 ppm NO.

Fig. 3 is a graph summarizing dose response data on the effect of inhaled NO on canine platelet  
10 aggregation.

Fig. 4 is a graph comparing the intima/media ratio in control rats; rats exposed for two weeks to 20 ppm NO; rats exposed for two weeks to 80 ppm NO; and rats exposed for one week to 80 ppm NO, followed by one week of  
15 breathing air. The asterisk indicates value significantly differs from baseline ( $p < 0.05$ ).

#### Detailed Description

##### Thrombosis

The invention provides a simple, rapid, selective  
20 and efficacious method for treating, inhibiting or preventing a vascular thrombosis in a mammal, such as a human patient. The thrombosis to be treated, inhibited or prevented may result from any of the various causes of thromboses. For example, the type of thrombosis may be a  
25 posttraumatic arterial thrombosis. The thrombosis may be at any one of various locations in the mammalian body. For example, the thrombosis location may be arterial, venous, coronary, cerebral, femoral, renal or placental. Preferably, the location of the thrombosis treated,  
30 inhibited or prevented is not pulmonary.

Coronary thromboses are often associated with an acute ischemic coronary syndrome. Any thrombosis-related acute ischemic coronary syndrome may be treated, inhibited or prevented by the administration of inhaled

NO, according to this invention. The thrombosis-related acute ischemic coronary syndrome may be associated with, e.g., an artery-occluding disease or a vascular interventional procedure. Thrombosis-related acute  
5 ischemic coronary syndromes include, but are not limited to, myocardial infarction, unstable angina pectoris, thrombosis after coronary revascularization, and reocclusion after coronary thrombolysis. Coronary revascularization may be accomplished by various known  
10 vascular interventional procedures, e.g., PTCA, laser angioplasty, coronary artery bypass grafting, coronary artery atherectomy or coronary artery stents.

Inhaled NO may be used, according to this invention, to treat a mammal that has been identified as  
15 having an existing thrombosis. Mammals, and humans in particular, are known to display various signs and symptoms relating to the existence of a thrombosis, and may be identified thereby. The recognition of such signs and symptoms is within the skill of medical  
20 practitioners. Signs and symptoms of a thrombosis in a human patient include, but are not limited to, the following: chest pain, shortness of breath, paralysis, limb pain, myocardial infarction, angina pectoris, unstable angina pectoris, crescendo angina pectoris,  
25 ischemic congestive heart failure, cardiogenic shock, peripheral vascular disease and ischemic limb. In one embodiment of this invention, the identified mammal is a human who has a thrombosis, and the thrombosis to be treated by NO inhalation is manifested as a myocardial  
30 infarction.

Alternatively, inhaled NO also may be used to inhibit or prevent thrombosis development in a mammal that does not have an existing thrombosis but has been identified as being at risk of developing a thrombosis.  
35 Certain existing pathological conditions, e.g.,

atherosclerosis, are known to put an individual at risk of developing a thrombosis. In addition, certain vascular interventional procedures, e.g., balloon angioplasty and coronary artery bypass surgery, are known to put an individual at risk of developing a thrombosis. Accordingly, individuals diagnosed as having pathological conditions with which an increased risk of thrombosis is associated, individuals who have undergone one or more vascular interventional procedures, and individuals for whom one or more vascular interventional procedures are imminent, may be advantageously treated according to this invention.

Similarly, the identified mammal may be a human at risk of developing a thrombosis, where the risk is associated with an artery-occluding disease such as atherosclerosis. Individuals with such pathological conditions may be identified by methods known to medical practitioners trained in the relevant areas of medical practice.

In another embodiment of this invention, the risk is associated with a vascular interventional procedure such as angioplasty. In a particularly preferred embodiment, the identified mammal is a human at risk of developing a thrombosis as a result of a PTCA procedure.

## 25 Arterial Restenosis

The invention provides a simple, rapid, selective and efficacious method for treating, inhibiting or preventing arterial restenosis resulting from excessive intimal hyperplasia. Excessive intimal hyperplasia and arterial restenosis frequently occur following vascular interventional procedures such as angioplasty of any vessel (e.g., carotid, femoral, coronary, etc.); or any coronary revascularization procedure, including balloon

- 10 -

angioplasty, laser angioplasty, coronary artery bypass grafting, atherectomy or coronary artery stents.

Inhaled NO may be used, according to this invention, to treat a mammal that has been identified as  
5 having an existing arterial restenosis. Mammals are known to display various signs and symptoms relating to the existence of an arterial restenosis, and may be identified thereby. The recognition of such signs and symptoms is within the skill of medical practitioners.  
10 Signs and symptoms of a arterial restenosis in a mammal include, but are not limited to, the following: chest pain, shortness of breath, electrocardiographic changes and coronary angiographic findings. The objective of treating an existing arterial restenosis with inhaled NO  
15 is to reduce the thickness of the intima of a restenosed artery, so as to increase the diameter of the arterial lumen, i.e., reduce the pathological stricture.

Alternatively, inhaled NO may be used, according to this invention, to inhibit or prevent arterial  
20 restenosis in a mammal (e.g., a human) that does not have an existing arterial restenosis but has been identified as being at risk of developing an arterial restenosis. Certain vascular interventional procedures, e.g., PTCA and coronary bypass surgery, can cause arterial trauma.  
25 Arterial trauma is known to lead to excessive intimal hyperplasia and arterial restenosis. Therefore, those procedures put a patient at risk of developing an arterial restenosis. Accordingly, individuals who have undergone one or more vascular interventional procedures,  
30 and individuals for whom one or more vascular interventional procedures are imminent, may be advantageously treated according to this invention.

The inhaled NO is, for example, administered to a human patient who is scheduled to undergo a vascular  
35 interventional procedure. Inhaled NO may be administered

- 11 -

in advance of a vascular interventional procedure, to minimize the amount of intimal thickening that takes place following the arterial trauma normally associated with vascular interventional procedures. A patient  
5 receiving inhaled NO as a preventive measure before a vascular interventional procedure may or may not have an existing arterial restenosis. Alternatively, inhaled NO may be administered to a patient who has already undergone a vascular interventional procedure. In that  
10 situation, administration of the inhaled NO preferably will begin within hours of the vascular interventional procedure. Of course, one of skill in the art will recognize that inhaled NO may be administered before, during and after a vascular interventional procedure.  
15 Regardless of whether the inhaled NO is administered before, during or after the procedure, or all three, the inhaled NO may be administered continuously or intermittently.

#### Administration of Inhaled NO

20 Inhaled NO is preferably administered from a source of stored, compressed NO gas. Compressed NO gas may be obtained from a commercial supplier such as Airco (Murray Hill, NJ), typically as a mixture of 200-800 ppm NO in pure N<sub>2</sub> gas. The source of NO can be 100% NO, or  
25 diluted with N<sub>2</sub> or any other inert gas (e.g., helium). It is vital that the NO be obtained and stored as a mixture free of any contaminating O<sub>2</sub> or higher oxides of nitrogen, because such higher oxides of nitrogen (which can form by reaction of O<sub>2</sub> with NO) are potentially  
30 harmful to lung tissues. If desired, purity of the NO may be demonstrated with chemiluminescence analysis, using known methods, prior to administration to the patient. Chemiluminescence NO-NO<sub>x</sub> analyzers are commercially available (e.g., Model 14A, Thermo

Environmental Instruments, Franklin, MA). The NO-N<sub>2</sub> mixture may be blended with air or O<sub>2</sub> through, for example, calibrated rotameters which have been validated previously with a spirometer. The final concentration of NO in the breathing mixture may be verified with a chemical or chemiluminescence technique well known to those in the field (e.g., Fontijn et al., Anal. Chem. 42:575 (1970)). Alternatively, NO and NO<sub>2</sub> concentrations may be monitored by means of an electrochemical analyzer. Any impurities such as NO<sub>2</sub> can be scrubbed by exposure to NaOH solutions, baralyme, or sodalime. As an additional control, the FiO<sub>2</sub> of the final gas mixture may also be assessed. If desired, the ventilator may have a gas scavenger added to the expiratory outlet to ensure that significant amounts of NO will not escape into the adjacent environment.

In a hospital or emergency field situation, administration of NO gas could be accomplished, for example, by attaching a tank of compressed NO gas in N<sub>2</sub>, and a second tank of oxygen or an oxygen/N<sub>2</sub> mixture, to an inhaler designed to mix gas from two sources; by controlling the flow of gas from each source, the concentration of NO inhaled by the patient can be maintained at an optimal level. NO gas may also be mixed with room air, using a standard low-flow blender (e.g., Bird Blender, Palm Springs, CA). NO may be generated from N<sub>2</sub> and O<sub>2</sub> (i.e., air) by using an electric NO generator. Such a generator is described in Zapol U.S. patent application 07/850,383 (notice of allowance issued), which is hereby incorporated by reference. In addition, NO may be provided intermittently from an inhaler. The use of an inhaler may be particularly advantageous if a phosphodiesterase inhibitor is administered, orally or by inhalation, in conjunction with the NO.

- 13 -

NO may be administered to a mammal identified as having a thrombosis or arterial restenosis, or a mammal identified as being at risk for developing a thrombosis or arterial restenosis, at a concentration of from 0.1 ppm to 300 ppm in air, pure oxygen, or another suitable gas or gas mixture, for as long as needed. Preferably, the concentration will be between 1.0 and 200 ppm; and most preferably between 20 and 100 ppm (e.g., 30 ppm, 40 ppm, 50 ppm, 60 ppm or 80 ppm). The concentration may temporarily increased for short periods of time: e.g., 5 min at 300 ppm NO, when an immediate dramatic effect is desired. For the reasons explained below, concomitant treatment with a phosphodiesterase inhibitor may decrease the total dosage of NO required (or allow intermittent dosage) to produce a satisfactory anti-thrombotic or anti-restenosis effect.

For treatment, inhibition or prevention of arterial restenosis, it may be necessary to administer inhaled NO by nasal prongs, mask, tent, intra-tracheal catheter or endotracheal tube, for an extended period, i.e., days or weeks. The administration may be continuous, during the extended period. Alternatively, administration could be intermittent during the extended period. The administration of gaseous NO may be via spontaneous or mechanical ventilation.

#### Assessment of Effects of Inhaled NO

When inhaled NO is administered to treat, inhibit or prevent thrombosis or arterial restenosis, it is desirable to monitor the effects of the NO inhalation. Such monitoring can be used, in a particular individual, to verify desirable effects and to identify undesirable side effects that might occur. Such monitoring is also

- 14 -

useful in adjusting dose level, duration and frequency of administration of inhaled NO in a given individual.

Preferably, the effects of inhaled NO on a patient would be assessed by one or more of the following:

- 5 clinical manifestations such as chest pain; electrocardiography; serial analyses of vascular patency by ultrasound, coronary angiography or other means; and increases in levels of cGMP in plasma or platelets.

#### Phosphodiesterase Inhibitors

- 10 NO decomposes rapidly by reacting with molecular oxygen to produce nitrite and nitrate. In addition, NO entering the blood is rapidly inactivated by tight binding to hemoglobin. For these reasons, NO has only a short half-life in arterial blood. This means that  
15 inhaled NO advantageously avoids systemic vasodilation, an undesirable, potentially dangerous side effect associated with sustained systemic NO release from NO donor compounds.

- It may be desirable to prolong the beneficial  
20 effects of inhaled NO within the target cells or within cells interacting with the target cells in the lung. In the context of thrombosis inhibition, prevention and treatment, circulating platelets are the target cells. In the context of arterial restenosis inhibition,  
25 prevention and treatment, circulating platelets (and possibly white cells) are the cells which interact with the target cells in the vasculature.

- In determining how to prolong the beneficial effects of inhaled NO, it is useful to consider that one  
30 of NO's in vivo effects is activation of soluble guanylate cyclase, which stimulates production of guanosine-3',5'-cyclic monophosphate (cGMP). At least some of the beneficial effects of NO appear to result from NO's stimulation of cGMP biosynthesis. Accordingly,



- 15 -

in a preferred embodiment of the invention, a phosphodiesterase inhibitor is administered in conjunction with NO inhalation, to inhibit the breakdown of cGMP by endogenous phosphodiesterases.

5           The phosphodiesterase inhibitor may be introduced into the mammal by any suitable method, including via an oral, transmucosal, intravenous, intramuscular, subcutaneous or intraperitoneal route. Alternatively, the inhibitor may be inhaled by the mammal. For  
10 inhalation, the phosphodiesterase inhibitor is advantageously formulated as a dry powder or an aerosolized solution having a particle or droplet size of less than 10  $\mu\text{m}$  for optimal deposition in the alveoli, and may optionally be inhaled in a gas containing NO.

15           A preferred phosphodiesterase inhibitor is Zaprinast<sup>®</sup> (M&B 22948; 2-o-propoxyphenyl-8-azapurine-6-one; Rhone-Poulenc Rorer, Dagenham Essex, UK). Zaprinast<sup>®</sup> selectively inhibits the hydrolysis of cGMP with minimal effects on the breakdown of cAMP in vascular  
20 smooth muscle cells (Trapani et al., J. Pharmacol. Exp. Ther. 258:269 (1991); Harris et al., J. Pharmacol. Exp. Ther. 249:394 (1989); Lugnier et al., Biochem. Pharmacol. 35:1743 (1986); Souness et al., Br. J. Pharmacol. 98:725 (1989)). When using Zaprinast<sup>®</sup> according to this  
25 invention, the preferred routes of administration are intravenous or oral. The suitable dose range may be determined by one of ordinary skill in the art. A stock solution of Zaprinast<sup>®</sup> may be prepared in 0.05 N NaOH. The stock can then be diluted with Ringer's lactate  
30 solution to the desired final Zaprinast<sup>®</sup> concentration, immediately before use.

          This invention may be practiced with other phosphodiesterase inhibitors. Various phosphodiesterase inhibitors are known in the art, including dipyridamole  
35 and theophylline. As with Zaprinast<sup>®</sup>, the route of

administration and suitable dose range may be determined by one of ordinary skill in the art.

Other Antithrombotic Agents in Conjunction with Inhaled NO

5           Thrombosis may be treated by agents that inhibit thrombus formation, agents that stimulate thrombolysis, i.e., thrombus dissolution, or both. Examples of antithrombotic agents are aspirin, streptokinase, urokinase, tissue plasminogen activator ("t-PA"), met-t-  
10 PA (i.e., t-PA with an N-terminal methionine residue), FE1X (a t-PA analog) heparin, hirudin and Hirulog<sup>®</sup> (a hirudin analog). Other antithrombotic agents could also be used in the practice of this invention. One or more such antithrombotic agents may be administered to a  
15 mammal before, during or after treatment with inhaled NO, so that their separate antithrombotic activity is advantageously used to augment the antithrombotic effect(s) of inhaled NO.

For example, in one embodiment of this invention,  
20 an appropriate dose of t-PA is administered before, during or immediately after NO inhalation, to treat thrombosis. While the inhaled NO is inhibiting or preventing the formation of new thrombi, the t-PA will stimulate the dissolution of: (1) thrombi already  
25 present at the time inhaled NO was administered, or (2) thrombi formed (albeit at a reduced rate) during or immediately after the NO inhalation. The selection of appropriate antithrombotic agents to be administered in conjunction with inhaled NO, and the selection of the  
30 appropriate dosage and route of administration of those antithrombotic agents is within ordinary skill in the art.

In a preferred embodiment of this invention, aspirin is administered before, during or immediately

- 17 -

after NO inhalation, to treat thrombosis. The preferred aspirin dose range is 81 to 325 mg (orally) per day.

While the two aspects of this invention (i.e., thrombosis and arterial restenosis) have been described separately, it should be appreciated that an individual may already have, or be at risk of developing, both a thrombosis and arterial restenosis. Under such circumstances, both aspects of the invention could be practiced at the same time, in the same individual, with a single administration of inhaled NO.

### Experimental Information

#### Thrombosis Experiments

The antiplatelet effects of NO have been assessed in a recognized canine model of acute coronary thrombolysis after thrombus formation. The canine model used was essentially as described by Yasuda et al. (J. Am. Coll. Cardiol. 13:1409 (1989)) and Gold et al. (Circulation (suppl. IV) 83:IV26 (1991)).

Twenty-five adult mongrel dogs (20-25 kg) of either sex were anesthetized with pentobarbital (30 mg/kg body weight). Supplemental pentobarbital was administered as required to maintain general anesthesia. The dogs' tracheas were intubated and their lungs were mechanically ventilated at 15 breath/min and 10-15 ml/kg with a ventilator at  $F_{IO_2}$  within 21-35% (Hudson Ventronics, Tenecula, CA) and adjusted to maintain the arterial blood  $O_2$  between 80 and 100 torr. The oxygen saturation was continuously monitored during the experiment, using a pulse oximeter (Nellcor, Inc., Hayward, CA).

The femoral artery and vein were cannulated with a polyvinyl chloride catheter for continuous arterial pressure, blood sampling and infusion. Lidocaine 0.1 mg/kg/min i.v., was given when arrhythmias occurred.

- 18 -

Thoracotomy was performed through the left fifth intercostal space. The pericardium was opened and suspended to create a pericardial cradle. The left anterior descending artery was dissected out free, and a 5 2.5 cm segment was isolated distal to the first diagonal branch. One milliliter of blood was withdrawn for thrombus formation. A 0.7 mm i.d. catheter was inserted into a side branch of the isolated left anterior descending coronary artery segment, and an ultrasonic 10 flow probe (T101 Transonic System, Inc., Ithaca, NY) was placed on the proximal portion of the artery for continuous blood flow monitoring. A 2 mm wide plastic wire (Mass Gas and Electric Supply, Watertown, MA) was progressively constricted around the left anterior 15 descending artery, just distal to the proposed site of thrombus formation, to limit blood flow to  $50 \pm 10\%$  of baseline. Previous angiographic study has shown this to decrease the luminal diameter by more than 90%.

The isolated left anterior descending coronary 20 artery was traumatized by four consecutive external compressions with blunted forceps during 3-5 seconds, to damage the endothelium and promote thrombus adherence. Snare occlusions were made distal to the probe and proximal to the constriction site. Thrombin (0.1 ml of 25 100 units/ml; Thrombinar, Armour Pharmaceutical, Kankakee, IL) mixed with 0.3 ml of blood was injected through the side branch catheter into the emptied coronary artery segment to induce thrombus formation. After 10 minutes, the proximal snare was released. Two 30 minutes later, the distal snare was released. Ten minutes after thrombus formation, a heparin bolus (75 UI/kg) was administered intravenously and followed by a continuous heparin infusion (50 UI/kg/h). After a 30-minute period of stable occlusion, recombinant

- 19 -

t-PA boluses (0.45 mg/kg; Activase<sup>TM</sup>, Genentech Inc., South San Francisco, CA) were administered at 15-minute intervals, until recanalization of the thrombosed coronary artery was achieved or a maximum of four boluses 5 had been administered.

This procedure induced alternating periods of recanalization and reocclusion (defined as less than 25% of poststenotic flow) after initial reflow of the left descending coronary artery. The ratio opening time/total 10 time was recorded as the primary outcome variable. ECG, systemic arterial pressure, left atrial pressure and coronary blood flow were continuously recorded. Animals with: (1) no reperfusion, (2) reperfusion without occlusion, (3) fewer than 3 cycles during the first 45- 15 minute observation period, or (4) death before the end of the first observation period, were excluded from further study.

NO gas (800 ppm NO in nitrogen, Airco, Murray Hill, NJ) was mixed with room air using a standard low- 20 flow blender (Bird Blender, Palm Springs, CA) and then titrated with varying quantities of NO, to maintain a constant  $F_{iO_2}$  just prior to delivery to the ventilator. Inspired NO level was continuously monitored by a chemiluminescence NO-NO<sub>x</sub> analyzer (Model 14A, Thermo 25 Environmental Instruments, Franklin, MA; Fontijn et al., supra). The  $F_{iO_2}$  was measured (oxygen meter No. 5590, Hudson, Temecula, Calif.) distal to the reservoir bag after the NO-containing gases were mixed. The exhaled gases, as well as those discharged from the 30 chemiluminescence analyzer, were scavenged by use of a venturi exhalation trap maintained at negative atmospheric pressured by the laboratory's central vacuum system. The ambient NO/NO<sub>2</sub> levels, as measured 35 intermittently by chemiluminescence, did not increase during the experiments. At each time samples were taken

- 20 -

and methemoglobin levels were measured. Heart rate, blood pressure and coronary flow were monitored and recorded continuously.

After a 45 minute baseline study period  
5 (pretreatment period) the animals were divided into four groups: Group A (n=6) was given 0 ppm inhaled NO (i.e., air) for 45 minutes; Group B (n=6) was given 20 ppm inhaled NO for 45 minutes; Group C (n=6) was given 80 ppm inhaled NO for 45 minutes and Group D (n=6) was given 200  
10 ppm for 45 minutes. All groups of animals were then observed for a third study period beginning with the cessation of NO administration and lasting 45 minutes (posttreatment period).

#### In Vitro Measurement of Platelet Aggregation

15 Blood from 8 dogs was collected in 0.01M citrate and centrifuged at room temperature at 370 x g for 5 minutes, for the preparation of platelet-rich plasma (PRP), and at 1200 x g for 10 minutes, for the preparation of platelet-poor plasma (PPP). PRP was  
20 exposed only to plastic containers or, during testing, siliconized glassware. The platelet count (Thrombocounter C<sup>™</sup> platelet counter, Coulter Electronics, Inc., Hialeah, FL) of PRP was adjusted by dilution with PPP to obtain  $300,000/\text{mm}^3 \pm 10\%$ . PRP was then aliquoted  
25 into cuvettes incubated at 37°C with magnetic stirring (1000 rpm) in a dual channel aggregometer (Model 440, Chrono-Log Corp., Havertown, PA). Light transmission was continuously recorded on a recorder (Model 707, Chrono-Log Corp., Havertown, PA). The aggregation sample tube  
30 was obstructed with a rubber cap and two 19 gauge needles (Sherwood Medical, St. Louis, MO) were placed through this cap, allowing the delivery of a mixture of NO gas and oxygen above the PRP. The inlet needle was connected via a flowmeter to a gas reservoir into which a mixture

- 21 -

of NO gas, air and oxygen titrated as described above was delivered. The NO concentration was continuously monitored by the chemiluminescence NO-NO<sub>x</sub> analyzer. A needle valve allowed regulation of the flow through the sample to approximately 40 ml/min. Positive pressure was maintained in the system by having the outlet needle connected to a recipient flask filled with 5 cm of water in which constant bubbling was maintained.

ADP-induced platelet aggregometry studies were performed after the exposure of the test cuvette containing 450 $\mu$ l of adjusted PRP to the NO gas mixture for 10 minutes. Gas administration was continued during the measurement of ADP-induced aggregation. Platelet aggregation was studied using different aliquots of PRP treated with 20, 80, 200 and 400 ppm of NO, in random order. Control ADP-induced platelet aggregation studies without NO were performed before and after the administration of NO to assess the stability of the PRP preparation. All experiments were completed within 4 hours of blood collection.

#### Data Analysis

Artery patency was defined as the fraction of the total observation period during which flow was greater than 25% of the basic flow after the initial stenosis was created. Except as noted, results are expressed as mean  $\pm$  SEM. The significance of differences between groups was determined with Student's t-test for paired or unpaired values as appropriate. The significance of the dose response of the effect of NO on ADP-induced platelet aggregation was assessed with two-way analysis of variance. A p value <0.05 was considered significant.

- 22 -

**Canine Thrombolysis and Reperfusion Model Results**

In each experimental group, the external constrictor reduced left anterior descending artery blood flow by  $54 \pm 2\%$  of baseline, from  $22 \pm 2$  to  $10 \pm 1$  5 ml/min. The median number of tPA boluses required to obtain reperfusion was two, with a range of 1 to 4 (Table 1). Cyclic reflow and reocclusion accompanied by electrocardiographic evidence of myocardial injury occurred in all animals except one in which reocclusion 10 did not occur; this animal was excluded from further study.



**TABLE 1**  
**Baseline Values of Physiological Parameters**

Parameter Measured	Group A 0 ppm NO (n=6)	Group B 20 ppm NO (n=6)	Group C 80 ppm NO (n=6)	Group D 200 ppm NO (n=6)
Post-stenotic flow (% before stenosis)	51.7±3.5	55.2±3.7	51.6±4.7	54.6±1.9
Number of tPA boluses	2.0±0.4	1.7±0.2	1.8±0.3	2.0±0.4
ACT (sec)	219±16	219±14	236±5.3	196±12.8
FIO <sub>2</sub> (%)	29.0±1.1	27.5±1.0	32.2±1.5	31.6±3.0
Ratio (%)	55.7±8.5	50.6±6.9	48.8±2.9	45.2±5.6
Hb(mg/dl)	13.26±1.35	14.28±0.85	14.08±0.85	12.95±0.6 <sub>4</sub>
Platelet Ct (x10 <sup>3</sup> /mm <sup>3</sup> )	301±55	292±25	277±35	237±35
Methb (%)	0.25±0.17	0.10±0.06	0.18±0.09	0.26±0.09

In Table 1: "Number of tPA boluses" refers to number of boluses injected; "ACT" refers to activated clotting time; "FIO<sub>2</sub>" refers to inspired O<sub>2</sub> fraction; "Ratio" refers to unoccluded/occluded coronary artery at  
5 baseline; "Platelet Ct" refers to platelet count; and "MetHb" refers to methemoglobin (percentage of total hemoglobin). There is no significant difference between the baseline flow rate ratios at 0 ppm (control), 20 ppm, 80 ppm and 200 ppm of inhaled NO (n=6 for each group).

#### 10 Effects of Inhaled NO on Artery Patency

In animals receiving 0 ppm inhaled NO (Group A), arterial patency did not change during the three treatment periods (Fig. 1A). In animals receiving 20 ppm inhaled NO (Group B), arterial patency increased from  
15  $50.6 \pm 6.9\%$  during the pre-inhalation baseline period, to  $63.8 \pm 7.9\%$  during the inhalation period ( $p < 0.01$ ) (Fig. 1B). In animals receiving 80 ppm inhaled NO (Group C), arterial patency increased from  $48.8 \pm 2.9\%$  during the pre-inhalation baseline period, to  $75.1 \pm 6.7\%$  during the  
20 inhalation period ( $p < 0.01$ ) (Fig. 1C). In animals receiving 200 ppm inhaled NO (Group D), arterial patency increased from  $45.27 \pm 5.6\%$  during the pre-inhalation baseline period to  $54.8 \pm 10.4\%$  during the inhalation period ( $p = \text{NS}$ ) (Fig. 1D). In group C the increased  
25 arterial patency observed during the NO inhalation period persisted during the 45-minute post-inhalation period ( $70.1 \pm 7.1\%$  vs. baseline,  $p < 0.05$ ).

When the inhalation period arterial patency results from groups B, C, and D were pooled, there was a  
30 statistically significant difference between the pooled treatment groups and the control group ( $p < 0.005$ ). When the 45-minute post-inhalation period artery patency results from groups B, C, and D were pooled, there was

- 25 -

also a statistically significant difference between the pooled treatment groups and the control group ( $p < 0.005$ ).

Neither platelet count nor blood hemoglobin  
5 changed during or after NO administration in any of the groups of animals (Table 3). Methemoglobin levels increased from  $0.2 \pm 0.1\%$  to  $1.1 \pm 0.4\%$  in the dogs breathing 200 ppm inhaled NO (Table 3). This increase persisted after the NO administration was stopped and was  
10 not seen in dogs receiving lower doses of NO.

Systemic arterial pressure decreased in all groups of dogs during this study, and did not differ between the dogs receiving NO and those who did not (Table 2A). Left atrial pressure was unchanged in all groups of animals  
15 throughout the duration of the study (Table 2B).

**TABLE 2A**  
**Mean Systemic Arterial Pressure (SAP) (mmHG)**  
**Before, During and After NO Inhalation**

NO Treatment	Before	During	After
0 ppm NO (N=6) Group A	89±8	82±6	80±7
20 ppm NO (n=6) Group B	105±6	96±6	82±6
80 ppm NO (n=6) Group C	91±5	81±9	78±7
200 ppm NO (n=6) Group D	94±3	95±4	93±4

Values are expressed as mean±SEM.

TABLE 2B

Mean Left Atrium Pressure (LAP) (mmHG)  
Before, During and After NO Inhalation

NO Treatment	Before	During	After
0 ppm NO (N=6) Group A	5.5±0.6	5.4±0.7	5.4±0.7
20 ppm NO (n=6) Group B	5.2±1.6	4.7±1.4	4.6±1.1
80 ppm NO (n=6) Group C	5.3±0.6	5.2±0.6	4.9±0.6
200 ppm NO (n=6) Group D	4.6±1.1	4.2±0.9	3.7±0.8

Values are expressed as mean±SEM.

Effects of NO on ADP-Induced In Vitro Platelet Aggregation

5 Addition of 20, 80, 200 and 400 ppm NO to the gas mixture above the PRP led to a dose-related decrease in the maximal change in light transmission caused by ADP (Fig. 3). There was no change in the ADP-induced decrease in light transmission in the two control aggregation curves performed at the beginning and end of each study ( $30.57 \pm 5.57\%$  vs.  $31.1 \pm 4.31\%$ ).

**TABLE 3**  
**Hematologic Values Before, During and After NO Inhalation**

NO Treatment	Measurement	Before	During	After
0 ppm NO Group A (n=6)	Hb (mg/dl)	13.2±1.3	13.7±0.8	12.2±0.7
	Platelet Count ( $\times 10^3/\text{mm}^3$ )	301±55	284±53	276±35
	MetHb (%)	0.22±0.2	0.2±0.1	0.2±0.2
20 ppm NO Group B (n=6)	Hb (mg/dl)	14.3±0.85	12.7±0.7	2±1
	Platelet Count ( $\times 10^3/\text{mm}^3$ )	292±25	269±22	253±16
	MetHb (%)	0.1±0.1	0.4±0.2	0.1±0.02
80 ppm NO Group C (n=6)	Hb (mg/dl)	14.0±0.8	11.9±0.3	11.1±0.6
	Platelet Count ( $\times 10^3/\text{mm}^3$ )	277±35	238±32	209±37
	MetHb (%)	0.2±0.1	0.4±0.1	0.3±0.1

- 30 -

The above results demonstrate that inhaled NO increases coronary artery patency after lysis of a thrombus at the site of a critical stenosis without producing any systemic hemodynamic effects. They also  
5 show that the antithrombotic effects of inhaled NO persist for at least 45 minutes after cessation of NO inhalation. At NO concentrations similar to those obtained in vivo, gaseous NO markedly inhibited ADP-induced platelet aggregation in vitro.

#### 10 Intimal Hyperplasia Experiments

Neointimal smooth muscle cell hyperplasia is the main pathologic process in human arterial restenosis. Therefore, to elucidate the effect of inhaled NO on the process of restenosis after a vascular interventional  
15 procedure such as PTCA, the effect of inhaled NO on intimal hyperplasia was studied, using a rat carotid artery model of arterial injury (Clowes et al., Laboratory Invest. 49:327 (1983)), a standard animal model for human neointimal smooth muscle cell  
20 hyperplasia.

#### Arterial Injury

Adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) underwent balloon injury of the common carotid artery in a manner previously shown to  
25 bring about neointimal hyperplasia (Clowes et al., supra). Rats weighing 300 to 350 g were anesthetized by intraperitoneal injection of ketamine (60-80 mg/kg) and acepromazine (0.1 mg/kg). Once satisfactory anesthesia had been achieved, a longitudinal midline incision was  
30 made and the left carotid artery was isolated via blunt dissection. After further careful dissection of the internal and external carotid bifurcation, the distal external carotid segment was ligated with a 4-0 silk



- 31 -

suture. A small arteriotomy was made in the external carotid using microdissecting scissors and a 2 French Fogarty balloon catheter (Baxter Edwards LIS) was inserted through the arteriotomy and advanced approximately two centimeters below the carotid bifurcation. The balloon was filled with enough saline to cause visible distention of the common carotid artery and gently withdrawn to the level of the bifurcation. The balloon catheter was then withdrawn and after allowing back bleeding through the arteriotomy site to eliminate potential thrombus and air bubbles, the external carotid was ligated proximal to the arteriotomy site using 4-0 silk sutures. After visual inspection to insure adequate pulsation of the common carotid artery, the surgical lesion was closed and the animals were allowed to recover from anesthesia.

#### Chronic NO Inhalation

Chronic NO inhalation was carried out in specially prepared 40 liter acrylic inhalation chambers. The gas mixtures were blended using separately regulated and calibrated flow meters for oxygen, pressurized air and NO stock gases (800 ppm and 10,000 ppm NO in N<sub>2</sub>, Airco, Murray Hill, NJ). The effluent gas from the chamber was analyzed periodically throughout the experimental period, to ensure stable FIO<sub>2</sub> and NO levels. The FIO<sub>2</sub> was measured using a polarographic electrode (Hudson Oxygen Meter 5590, Temecula, CA); NO concentration was measured by chemiluminescence (Model 14A, Thermo Environmental Instruments, Inc., Franklin, MA); and nitrogen dioxide and nitrogen with higher oxidation states (NO<sub>x</sub>) were measured by chemiluminescence following conversion of the NO<sub>x</sub> to NO by a heated stainless steel oven (850°C) with 98% efficiency (Model 100B NO<sub>x</sub> generator, Thermo Environmental Instruments, Inc., Franklin, MA). Fresh

- 32 -

soda lime was maintained in the chambers to reduce  $\text{NO}_x$ . NO concentration was maintained at 20 to 80 ppm, depending upon the experiment. Serial measurements revealed  $\text{FIO}_2$  to be 21% and  $\text{NO}_x$  to be 3-4 ppm. The gases exiting the exposure chambers, as well as those discharging from the chemiluminescence instrument, were scavenged using a venturi trap maintained at negative atmospheric pressure with reference to the laboratory's central vacuum system.

Control animals were maintained in filtered cages in the same room as the NO-treated animals. The NO exposure was begun 30 to 120 minutes prior to the surgical procedure. During the surgical procedure, the NO-treated group was taken out of the chamber and exposed to NO by a modified face mask fed from the inflow gas tubing of the chambers. Inhaled gas analysis revealed NO levels of 50-80 ppm during the 80 ppm experiments and 10-20 ppm during the 20 ppm surgical experiments. The total time each animal was out of the chamber and under the face mask ranged from 20 to 40 minutes.

#### Morphometric Analysis

At 1, 3 and 14 days after balloon injury, the rats were euthanized by lethal intraperitoneal injection of sodium pentobarbital or ketamine. A 16 gauge catheter was introduced into the ascending aorta via the left ventricular apex. The descending thoracic aorta was ligated. The animal was then perfused at a pressure of 100 mm Hg with 100 ml of normal saline followed by 50 ml of 2% paraformaldehyde in phosphate buffered saline (PBS). After in vivo fixation for 15 to 30 minutes, both common carotid arteries were isolated and underwent further overnight fixation by immersion in 1% paraformaldehyde in PBS. The tissue was dehydrated using sequentially increasing concentrations of ethanol

- 33 -

followed by xylene, and then embedded in paraffin. Cross sections (6  $\mu$ m) were cut and stained with hematoxylin and eosin and/or elastin for analysis. A single section 7 to 8 mm proximal to the carotid bifurcation was used for analysis in each animal. The section being analyzed was photographed at 100X. The image was digitized using a Kodak 2135<sup>™</sup> scanner. The intimal and medial area analyses were performed on a Power Macintosh 8100/80<sup>™</sup> computer using the public domain NIH Image program (written by Wayne Rasband at the U.S. National Institutes Of Health and available from the Internet by anonymous ftp from zippy.nimh.nih.gov or on floppy disk from NTIS, 5285 Port Royal Rd., Springfield, VA 22161; part number PB93-504868). The morphometric analysis was performed with the investigator blinded as to the experimental group.

#### Statistical Analysis

Statistical analysis was carried out utilizing commercially available Statview<sup>™</sup> (Abacus Concepts) software for Macintosh<sup>™</sup> computers. The experimental group was compared with the control group using an unpaired two tailed t-test. A value of  $P < 0.05$  was considered statistically significant. All data are represented as mean  $\pm$  SEM. The n value refers to the number of animals per group.

#### Results from Rodent Model of Restenosis

A total of 62 rats underwent the carotid injury procedure. Five of the rats died due to vascular complications during the arteriotomy or the balloon injury, giving a procedure mortality rate of 8%. There was no statistically significant maldistribution of the deaths among the different experimental groups. There were no post-procedure deaths among the 57 rats who

- 34 -

survived the initial procedure. All rats, regardless of their experimental group, exhibited normal grooming behavior and activity levels throughout the study. Other than occasional ptosis on the side of the carotid injury, no rats exhibited a gross neurological deficit. Analysis of a subset of the experimental groups revealed weight gain without statistical difference during exposure to air, NO at 20 ppm and NO at 80 ppm.

10 In the first series of experiments, the rats undergoing carotid balloon injury were exposed to either ambient air (n = 12) or 80 ppm NO (n = 13) in air, throughout the duration of the study. The animals were sacrificed 14 days after injury for morphometric analysis of the injured carotid artery. Examination by light microscopy revealed that three rats from the air (control) group and one rat from the NO-treated group had thrombotic occlusion of the lumen of the injured carotid. These animals were excluded from further analysis. As expected, blood vessels from both groups exhibited a loss of endothelium and the development of neointimal hyperplasia. Examination by light microscopy did not reveal a qualitative difference in the cellular morphology of the neointima (data not shown). Quantitative analysis, however, revealed that the 80 ppm inhaled NO treatment resulted in a 38% inhibition of neointimal hyperplasia, i.e., intima/media ratio of  $0.932 \pm 0.13$  in 80 ppm animals, compared to  $1.512 \pm 0.147$  in 0 ppm NO (control) animals ( $P = 0.008$ ) (Fig. 4).

30 In the next series of experiments, the effect of a one week exposure to NO was tested. The experimental group (n = 7) was exposed to 80 ppm NO for seven days and then transferred to air for an additional seven days, prior to sacrifice. The control group (n = 5) was exposed to air for the entire 14 day period. There was

- 35 -

no qualitative morphologic difference between the groups. In addition, quantitative analysis of the intima/media ratio revealed no significant difference in neointimal hyperplasia between the two groups, i.e.,  $1.059 \pm 0.239$  in NO-treated animals, compared to  $1.217 \pm 0.309$  in controls ( $P = \text{not significant}$ ) (Fig. 4).

In a third series of experiments, a lower inhaled dose of NO was studied: the rats breathed either 20 ppm NO ( $n = 8$ ) or air ( $n = 8$ ). Again, no quantitative or qualitative difference in the degree of neointimal hyperplasia could be found between the 2 groups, i.e., intima/media ratio of  $0.917 \pm 0.233$  for 20 ppm NO-treated animals, compared to  $0.985 \pm 0.149$  for air-breathing controls ( $P = \text{not significant}$ ) (Fig. 4).

The above results demonstrate that inhalation of 80 ppm NO, over a two-week period, significantly inhibits neointimal hyperplasia following balloon-induced injury to carotid arteries, in a rodent model.

Other embodiments of the invention are within the following claims.

- 36 -

Claims

1. Use of gaseous NO for the manufacture of a medicament for treatment or prevention of arterial restenosis resulting from excessive intimal hyperplasia  
5 in a mammal.
2. The use of claim 1, wherein the treatment or prevention is by a method comprising the steps of:
  - (a) identifying a mammal that has an existing arterial restenosis or is at risk for developing arterial  
10 restenosis; and
  - (b) causing said mammal to inhale a therapeutically effective concentration of gaseous NO.
3. The use of claim 1 or 2, wherein said mammal is a human.
- 15 4. The use of claim 1 or 2, wherein said mammal has undergone or is preparing to undergo a vascular interventional procedure.
5. The use of claim 4, wherein said vascular interventional procedure is selected from the group  
20 consisting of angioplasty, coronary artery surgery and coronary artery stents.
6. The use of claim 5, wherein said procedure is percutaneous transluminal coronary angioplasty (PTCA).
7. The use of claim 1 or 2, wherein said NO is  
25 inhaled in a predetermined concentration range.
8. The use of claim 7, wherein said concentration range is 0.1 ppm to 300 ppm.

- 37 -

9. The use of claim 1 or 2, wherein said gaseous NO is inhaled as a mixture comprising NO, O<sub>2</sub>, and N<sub>2</sub> gases.

10. The use of claim 9, wherein said mixture  
5 comprises between 20% and 99% O<sub>2</sub> gas by volume.

11. The use of claim 9, wherein said O<sub>2</sub> is mixed with said NO immediately before said mixture is inhaled by said mammal.



12. The use of claim 1 or 2, further comprising  
10 the step of administering to said mammal, in conjunction with NO inhalation, a therapeutically effective amount of a second compound that potentiates the therapeutic effect of gaseous NO.

13. The use of claim 12, wherein said second  
15 compound is selected from the group consisting of a phosphodiesterase inhibitor and superoxide dismutase.

14. The use of claim 13, wherein said  
phosphodiesterase inhibitor is selected from the group  
consisting of 2-o-propoxyphenyl-8-azapurin-6-one  
20 (Zaprinast®), dipyridamole and theophylline.

15. The use of claim 1 or 2, wherein said gaseous NO is inhaled in the absence of tobacco smoke.



1 / 5




SUBSTITUTE SHEET (RULE 26)




2 / 5




SUBSTITUTE SHEET (RULE 26)

**FIG. 2**

SUBSTITUTE SHEET (RULE 26)

**FIG. 3**

**FIG. 4**

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/01745

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61L 9/04; A61K 9/12

US CL : 424/434, 44, 45; 514/957

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/434, 44, 45; 514/957

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US, A, 5,427,797 (FROSTELL ET AL) 27 June 1995, see the entire document.	1-15



Further documents are listed in the continuation of Box C.



See patent family annex.

•	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"Z"	document member of the same patent family

Date of the actual completion of the international search

27 MARCH 1996

Date of mailing of the international search report

04 APR 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FREDERICK KRASS

Telephone No. (703) 308-2351